Novartis Czech Republic - From EBITDA to Net Profit

Net Profit, EBIT & EBITDA (CZK mil)
Pharmaceutical | Czech Republic | November 10, 2018
$4.99
Excel Sheet

Novartis Czech Republic made a net profit of CZK 71.0 mil under revenues of CZK 6,312 mil in 2017, down -6.08% and -1.25%, respectively, when compared to the last year. This translates into a net margin of 1.12%.

Historically, the firm’s net profit reached an all time high of CZK 82.7 mil in 2015 and an all time low of CZK 2.15 mil in 2000. Since 2012, the firm's net profit has increased 42.1% or 7.27% a year on average.

On the operating level, EBITDA reached CZK 138 mil, up -18.9% when compared to the previous year. Over the last five years, company's EBITDA has grown 14.6% a year on average.

You can see all the company’s data at Novartis Czech Republic Profile, or you can download a report on the company in the report section.

Net Profit Unit 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic CZK mil 46.2 28.3 28.7 40.5 35.8
Bayer Czech Republic CZK mil 166 83.4 96.2 107 123
GlaxoSmithKline Czech Republic CZK mil 240 164 127 87.7 125
Merck Czech Republic CZK mil 49.3 63.4 27.4 34.9 68.6
Novartis Czech Republic CZK mil 41.7 50.0 52.3 82.2 82.7
Pfizer Czech Republic CZK mil 231 48.1 144 134 75.4
Roche Czech Republic CZK mil 50.5 38.7 135 94.9 51.0 ...
Sanofi-Aventis Czech Republic CZK mil 55.1 45.2 65.2 1.19 58.6
Servier Czech Republic CZK mil ... ... 12.8 13.6 13.6 15.9
Walmark CZK mil 214 -3.00 -8.61 41.8 -716
AVERAGE CZK mil 82.6 122 53.1 68.1 63.7 -7.96 58.2 65.9